Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Clinical Study of TAS0313 in Patients with Solid Tumor

Next Previous
Trial Profile

Phase I/II Clinical Study of TAS0313 in Patients with Solid Tumor

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAS-0313 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Duodenal cancer; Gallbladder cancer; Giant cell tumours; Glioblastoma; Gliosarcoma; Haemangioendothelioma; Lung cancer; Mesothelioma; Mouth neoplasm; Neuroendocrine carcinoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Taiho Pharmaceutical

Most Recent Events

  • 01 Nov 2022 Results from Phase 2 part evaluated the efficacy and safety of TAS0313 in patients with GBM, published in the Cancer Immunology Immunotherapy
  • 11 Oct 2022 Status changed from recruiting to suspended, as per JapicCTI record
  • 08 Jun 2021 Results of an analysis assessing the efficacy of TAS0313 in combined with Pembrolizumab for locally advanced or metastatic Urothelial carcinoma presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top